Status of the ongoing SORENTO clinical trial: Assessing efficacy and safety of high-exposure octreotide subcutaneous depot in patients with GEP-NET

#4156

Introduction: Somatostatin receptor ligands (SRLs) are first-line standard of care therapies for gastroenteropancreatic neuroendocrine tumors (GEP-NET). Retrospective data suggest higher-dose SRLs may benefit patients with GEP-NET.

Aim(s): The aim of this clinical trial is to confirm efficacy/safety of a long-acting, high-exposure formulation octreotide subcutaneous depot (CAM2029), versus octreotide LAR and lanreotide Autogel (ATG).

Materials and methods: SORENTO (NCT05050942) is a randomised, multicentre, open-label, active-controlled phase 3 trial, aiming to enrol 302 patients with GEP-NET. Key eligibility criteria: advanced, well-differentiated NET of GEP/presumed GEP origin; ≥1 measurable somatostatin receptor-positive lesion; no/

Conference:

Presenting Author: Singh S

Authors: Singh S, Capdevila J, Ang Chan J, de Herder W, Grozinsky-Glasberg S,

Keywords: CAM2029, GEP-NET, high plasma exposure, octreotide, randomised active-controlled, somatostatin receptor ligands, SORENTO,